Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group‐American College of Radiology Imaging Network (ECOG‐ACRIN) E2805

2021 ◽  
Author(s):  
Jose A. Karam ◽  
Maneka Puligandla ◽  
Keith T. Flaherty ◽  
Robert G. Uzzo ◽  
Surena F. Matin ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Adjuvant Therapy ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Eastern Cooperative Oncology Group ◽  
Oncology Group ◽  
Post Hoc Analysis ◽  
Sarcomatoid Renal Cell Carcinoma ◽  
Post Hoc

scholarly journals Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG‐ACRIN E2805 trial

2021 ◽  
Author(s):  
Caitlin C. Murphy ◽  
Hannah M. Fullington ◽  
David E. Gerber ◽  
Isaac Alex Bowman ◽  
Maneka Puligandla ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Post Hoc Analysis ◽  
Post Hoc

scholarly journals COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma

2019 ◽  
Vol 17 (6) ◽  
pp. 425-435.e4 ◽  
Author(s):  
Cora N. Sternberg ◽  
Robert J. Motzer ◽  
Thomas E. Hutson ◽  
Toni K. Choueiri ◽  
Christian Kollmannsberger ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Post Hoc Analysis ◽  
Post Hoc

scholarly journals Sarcomatoid Renal Cell Carcinoma: The Present and Future of Treatment Paradigms

Kidney Cancer ◽  
2021 ◽  
pp. 1-13
Author(s):  
Nellowe Candelario ◽  
Christopher Geiger ◽  
Thomas Flaig
Keyword(s):  
Renal Cell Carcinoma ◽  
Clinical Trials ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Checkpoint Inhibitors ◽  
Poor Response ◽  
Future Research ◽  
Sarcomatoid Renal Cell Carcinoma ◽  
Post Hoc

Sarcomatoid renal cell carcinoma (sRCC) is an aggressive form of kidney cancer that is associated with poor prognosis. It can arise from any histologic type of renal cell carcinoma. The majority of cases will present with advanced or metastatic disease requiring systemic therapy. Nephrectomy is the treatment of choice in locally resectable disease. The therapeutic options for sRCC have evolved in the past decade. Cytotoxic chemotherapy and monotherapy with targeted therapy (VEGF and mTOR) have historically shown poor response rates and survival in the treatment of metastatic sRCC. The use of checkpoint inhibitors and their combination with targeted therapy against VEGF has changed the landscape and outcomes for renal cell carcinoma. Given the rarity of sRCC most of the data on treatment is from small cohorts or extrapolation from larger clinical trials. The benefit from the combination of checkpoint inhibitors and targeted therapy to VEGF has shown promise in the sRCC population in post hoc analysis of large clinical trials. Future research focusing on further characterizing the unique biologic and clinical features of sRCC is critical in advancing the knowledge and developing effective therapy to improve clinical outcomes and survival.

Sign in / Sign up

Export Citation Format

Share Document